AUPH
Aurinia Pharmaceuticals Inc
16.60$
+1.2%
vs. previous close
Closing price · As of: Sep 24, 2026
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 12.4% | 12.0% | 15.4% | 15.6% | 8.9% | 9.3% | 13.7% | 10.2% | 11.6% | 11.0% | 8.4% | 7.9% | 9.6% | |
| 87.6% | 88.0% | 84.6% | 84.4% | 91.1% | 90.7% | 86.3% | 89.8% | 88.4% | 89.0% | 91.6% | 92.1% | 90.4% | |
| 25.0% | 22.7% | 11.0% | 7.1% | 4.5% | 13.5% | 9.2% | 10.6% | 11.5% | 14.1% | 9.6% | 15.7% | 12.8% | |
| 87.6% | 111.0% | 88.3% | 71.2% | 55.9% | 52.1% | 31.0% | 36.0% | 34.8% | 36.9% | 27.9% | 28.2% | 31.9% | |
| 117.4% | 133.7% | 105.9% | 87.1% | 73.8% | 93.5% | 51.3% | 61.2% | 47.9% | 45.9% | 38.3% | 36.4% | 42.0% | |
| -29.8% | -45.7% | -21.3% | -2.6% | 17.3% | -2.8% | 35.0% | 28.7% | 40.5% | 43.1% | 53.3% | 55.7% | 48.4% | |
| 2.6% | 2.9% | 2.6% | 2.1% | 1.8% | 1.9% | 1.7% | 1.6% | 1.5% | 8.4% | 1.3% | 1.1% | 3.1% | |
| -24.1% | -58.6% | -19.9% | 2.6% | 21.8% | 2.0% | 39.0% | 31.6% | 43.5% | 46.3% | 56.5% | 58.6% | 51.5% | |
| 0.5% | 1.0% | 1.5% | 1.3% | 0.7% | -0.4% | 1.6% | 0.9% | 0.6% | -227.1% | 12.3% | 13.7% | -49.4% | |
| -24.7% | -59.6% | -21.4% | 1.3% | 21.2% | 2.4% | 37.4% | 30.7% | 42.9% | 273.4% | 44.2% | 45.0% | 100.8% | |
| -11.5% | -34.7% | -7.7% | 13.1% | 30.9% | 12.0% | 48.5% | 40.2% | 50.1% | 61.0% | 64.0% | 65.6% | 60.4% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: September 24, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.